Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6121050 | Journal of Clinical Virology | 2011 | 4 Pages |
Abstract
HBV reactivation can be a severe complication in onco-haematological patients undergoing chemotherapy with rituximab. In our experience all nucleos(t)ide analogues were safe and effective. Three patients seroconverted to HBsAb. This may be as a result of the antivirals enhancing the immune response to HBV. A similar role may also be played by immune recovery following the withdrawal of immune-suppressive treatment. This report confirms the importance of anti-viral prophylaxis in patients with a high risk of HBV reactivation.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Arturo Montineri, Luciano Nigro, Rosario La Rosa, Carmelo Iacobello, Licia Larocca, Elisa Cappello, Paolo Fabio Fiumara, Francesco Di Raimondo, Filippo Fatuzzo,